Professor TIAN Delu's medication experience in differentiating and treating liver fibrosis by stages based on the principle of "the liver, serving as a firm organ, being tempered by softness"

ZHOU Jingxin; SUN Huiyi; ZHANG Wen; NIE Lihong; WANG Wenying; LI Zhihong; TIAN Delu

doi:10.16025/j.1674-1307.2026.02.012

您当前的位置：

首页 >

文章列表页 >

Professor TIAN Delu's medication experience in differentiating and treating liver fibrosis by stages based on the principle of "the liver, serving as a firm organ, being tempered by softness"

更新时间：2026-04-08

- Professor TIAN Delu's medication experience in differentiating and treating liver fibrosis by stages based on the principle of "the liver, serving as a firm organ, being tempered by softness"
- Beijing Journal of Traditional Chinese Medicine Vol. 45, Issue 2, Pages: 217-221(2026)
- 作者机构：
  
  北京中医药大学东直门医院中内教研室，北京 101121
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2026.02.012
  CLC：
- Received：03 March 2025，
  
  Published：25 February 2026
- 稿件说明：
移动端阅览
周静鑫，孙慧怡，张雯，等.田德禄基于“肝为刚脏必柔以济之”分期辨治肝纤维化的用药经验［J］.北京中医药，2026，45（2）：217-221.

ZHOU Jingxin,SUN Huiyi,ZHANG Wen,et al.Professor TIAN Delu's medication experience in differentiating and treating liver fibrosis by stages based on the principle of "the liver, serving as a firm organ, being tempered by softness"[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(02):217-221.
周静鑫，孙慧怡，张雯，等.田德禄基于“肝为刚脏必柔以济之”分期辨治肝纤维化的用药经验［J］.北京中医药，2026，45（2）：217-221. DOI： 10.16025/j.1674-1307.2026.02.012.

ZHOU Jingxin,SUN Huiyi,ZHANG Wen,et al.Professor TIAN Delu's medication experience in differentiating and treating liver fibrosis by stages based on the principle of "the liver, serving as a firm organ, being tempered by softness"[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(02):217-221. DOI： 10.16025/j.1674-1307.2026.02.012.

摘要

肝纤维化归属于中医学“胁痛”“黄疸”“积聚”范畴。田德禄教授基于“肝为刚脏必柔以济之”的生理特性，认为肝纤维化是过食肥甘厚味、酒酪之品或病毒之外邪侵袭，致肝体用及气血失和，脏腑功能失调，湿、热、毒、郁、瘀等病理产物稽留胶结，凝滞肝络，肝体受损而发。初病多实，久则虚实夹杂，后期则正虚邪留。治疗当谨守病机，以“祛其邪，补其虚，调其气血”为治疗原则，分三阶段辨治，早期治以疏肝理气、活血化瘀、清利湿热，中期祛邪同时治以调肝理脾，后期治以扶正固本、补益肝脾肾，并将调血通络贯穿始终，复肝之刚柔相济的生理功能以逆转肝纤维化。

Abstract

Liver fibrosis falls within the categories of "hypochondriac pain"， "jaundice"， and "abdominal mass" in traditional Chinese medicine （TCM）. Based on the physiological characteristic that "the liver， serving as a firm organ， being tempered by softn

ess"， Professor TIAN Delu considers liver fibrosis to result from excessive consumption of rich， greasy， and alcoholic foods， or invasion by external pathogens such as viruses. These factors lead to disharmony of the liver's substance and function， as well as

and blood， resulting in dysfunction of the

Zang-fu

organs. Consequently， pathological products such as dampness， heat， toxin， stagnation， and blood stasis accumulate， congeal， and obstruct the liver collaterals， causing damage to the liver. In the early stage， the disease is predominantly characterized by excess； over time， it develops into a pattern of mixed deficiency and excess， and in the late stage， it is marked by deficiency of healthy

with persistence of pathogenic factors. Treatment should adhere to the pathogenesis， following the principle of "eliminating pathogenic factors， tonifying deficiency， and regulating

and blood"， with stage-based differentiation and management. In the early stage， treatment focuses on soothing the liver and regulating

， activating blood and resolving stasis， and clearing damp-heat. In the middle stage， while eliminating pathogenic factors， treatment also emphasizes regulating the liver and strengthening the spleen. In the late stage， therapy focuses on reinforcing healthy

and consolidating the root， tonifying the liver， spleen， and kidney. Throughout all stages， regulation of blood and unblocking of the collaterals are consistently applied to restore the physiological state of balance between firmness and softness of the liver， thereby reversing liver fibrosis.

关键词

Keywords

references

PINZANI M , ROMBOUTS K , COLAGRANDE S . Fibrosis in chronic liver diseases: diagnosis and management [J ] . J Hepatol , 2005 , 42 Suppl( 1 ): 22 - 36 .

DHAR D , BAGLIERI J , KISSELEVA T , et al . Mechanisms of liver fibrosis and its role in liver cancer [J ] . Exp Biol Med (Maywood) , 2020 , 245 ( 2 ): 96 - 108 .

HAMMERICH L , TACKE F . Hepatic inflammatory responses in liver fibrosis [J ] . Nat Rev Gastroenterol Hepatol , 2023 , 20 ( 10 ): 633 - 646 .

SCHUPPAN D , ASHFAQ-KHAN M , YANG AT , et al . Liver fibrosis: direct antifibrotic agents and targeted therapies [J ] . Matrix Biol , 2018 , 68-69 : 435 - 451 .

CALIGIURI A , GENTILINI A , PASTORE M , et al . Cellular and molecular mechanisms underlying liver fibrosis regression [J ] . Cells , 2021 , 10 ( 10 ): 2759 .

中华医学会肝病学分会 , 中华医学会消化病学分会 , 中华医学会感染病学分会 . 肝纤维化诊断及治疗共识(2019年) [J ] . 实用肝脏病杂志 , 2019 , 22 ( 6 ): 793 - 803 .

HU C , LI HX , ZHANG MT , et al . Structure characterization and anticoagulant activity of a novel polysaccharide from Leonurus artemisia (Laur.) S. Y. Hu F [J ] . RSC Adv , 2020 , 10 ( 4 ): 2254 - 2266 .

ZHANG L , KHOO CS , XIAHOU Z , et al . Antioxidant and anti-melanogenesis activities of extracts from Leonurus japonicus Houtt [J ] . Biotechnol Genet Eng Rev , 2024 , 40 ( 3 ): 2888 - 2909 .

卢丽娜 , 袁露 , 梁博志 , 等 . 益母草碱对异丙肾上腺素诱导大鼠心肌纤维化和miR-1表达的影响 [J ] . 中国病理生理杂志 , 2018 , 34 ( 11 ): 1928 - 1934 .

章忱 , 刘艳 , 吕嵘 , 等 . 益母草水提物对心室重构大鼠心肌胶原表达的影响 [J ] . 上海中医药大学学报 , 2011 , 25 ( 3 ): 76 - 79 .

FAN W , PAN M , ZHENG C , et al . Leonurine inhibits hepatic lipid synthesis to ameliorate NAFLD via the ADRA1a/AMPK/SCD1 axis [J ] . Int J Mol Sci , 2024 , 25 ( 19 ): 10855 .

ZHANG L , SHI J , SHEN Q , et al . Astragalus saponins protect against extrahepatic and intrahepatic cholestatic liver fibrosis models by activation of farnesoid X receptor [J ] . J Ethnopharmacol , 2024 , 318 ( Pt A ): 116833 .

DAN L , HAO Y , SONG H , et al . Efficacy and potential mechanisms of the main active ingredients of astragalus mongholicus in animal models of liver fibrosis: A systematic review and meta-analysis [J ] . J Ethnopharmacol , 2024 , 319 ( Pt 1 ): 117198 .

李淑娣 , 王振 , 刘江凯 , 等 . 基于细胞信号通路探讨黄芪活性成分抗肝纤维化的研究进展 [J ] . 中国药理学通报 , 2023 , 39 ( 1 ): 18 - 23 .

丁霞 , 田德录 , 焉小丽 , 等 . 调肝理脾方治疗酒精性肝纤维化的临床研究 [J ] . 北京中医药大学学报 , 2000 , 23 ( 1 ): 58 - 61 .

李丰衣 , 孙劲晖 , 田德禄 . 田德禄教授治疗酒精性肝纤维化经验浅探 [J ] . 吉林中医药 , 2006 , 26 ( 8 ): 10 - 11 .

李丰衣 , 孙劲晖 , 田德禄 , 等 . 调肝理脾方抗酒精性肝纤维化作用机制研究 [J ] . 山东中医药大学学报 , 2009 , 33 ( 3 ): 250 - 252 .

李丰衣 , 孙劲晖 , 田德禄 , 等 . 调肝理脾方抑制酒精性肝纤维化的实验研究 [J ] . 中国中西医结合消化杂志 , 2009 , 17 ( 1 ): 25 - 27 .

李丰衣 , 孙劲晖 , 田德禄 , 等 . 调肝理脾方对酒精性大鼠肝纤维化的抑制作用及其方证探讨 [J ] . 中西医结合肝病杂志 , 2008 , 18 ( 4 ): 240 - 242 .

孙劲晖 , 李丰衣 , 许文飞 . 调肝理脾方对大鼠酒精性肝纤维化HSC增殖相关因子PDGF、PDGFR表达的影响 [J ] . 中国老年保健医学 , 2005 , 3 ( 1 )： 22 - 24 .

丁霞 , 蒙一纯 , 田德禄 , 等 . 调肝理脾方对HSCDNA及RNA的影响 [J ] . 中国中医基础医学杂志 , 2000 ,( 12 ): 23 - 25 .

陈士铎 . 外经微言 [M ] . 北京 : 中国医药科技出版社 , 2011 : 22 .

李中梓 . 医宗必读 [M ] . 北京 : 人民卫生出版社 , 2019 : 28 .

林珮琴 . 类证治裁 [M ] . 北京 : 人民卫生出版社 , 2005 : 27 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Experience of TCM master CHAI Songyan in treating infertility based on the theory of "three theories of gynecology"

HU Kaiwen's experience in treating cancer-related insomnia by warming method

Treatment of insomnia with Shuangxia Decoction: YANG Weibin's clinical experience based on taking images for analogy

LUO Sulan's clinical experience in treating the extended distal radius fracture with "three-point technique"

HU Yinqi's experience of treating gout by stages from "dampness turbidity" "heat toxin" and "phlegm stasis"

Related Author

TONG Qing

GAO Hongyan

ZHOU Tian

ZHENG Hao

SHI Xiang

ZHU Miao

XU Jie

HU Kaiwen

Related Institution

Beijing University of Chinese Medicine

Department of Gynecology， Beijing Hospital of Traditional Chinese Medicine，Capital Medical University

Second Clinical Medical College， Beijing University of Chinese Medicine

Oncology Department， Dongfang Hospital， Beijing University of Chinese Medicine

Department of Rheumatology and Immunology， Guang'anmen Hospital， China Academy of Chinese Medical Sciences

⁰